A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter V. Morris
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors V. Morris1, K. Ciombor2, M. Salem3, H. Nimeiri4, S. Iqbal5, P. Singh6, B. Polite7, D. Deming8, E. Chan9, J. Wade10, T. Bekaii-Saab11, R. Wolff1, C. Eng1
  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, /
  • 2The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, Ohio, USA, /
  • 3Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, Ohio, USA, /
  • 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA, /
  • 5University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, USA, /
  • 6Mayo Clinic, Rochester, Minnesota, USA, /
  • 7The University of Chicago, Chicago, Illinois, USA, /
  • 8University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, USA, /
  • 9Vanderbilt University Medical Center, Nashville, Tennessee, USA, /
  • 10Cancer Care Center of Decatur, Decatur, Illinois, USA, /
  • 11Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA, /

Abstract

Worldwide, it is estimated that SCCA will develop in > 27,000 patients (pts). Twenty percent of pts will develop metastatic (met) disease for which there is no standard approach in the refractory setting. We have previously demonstrated that > 90% of metastatic SCCA is associated with HPV carcinogenesis. Nivolumab (Nivo), a monoclonal antibody targeting PD-1 on T cells, promotes immune-mediated anti-tumor activity of T cells against HPV-positive cells in vitro. We proceeded to conduct the first phase II trial of Nivo in previously treated met SCCA pts.